474 related articles for article (PubMed ID: 27875938)
1. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
[TBL] [Abstract][Full Text] [Related]
2. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
3. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis.
Han Y; Ma Z
Anticancer Drugs; 2021 Apr; 32(4):427-436. PubMed ID: 33587348
[TBL] [Abstract][Full Text] [Related]
4. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
5. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
8. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
9. Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway.
Yuan R; Chang J; He J
Cell Mol Biol (Noisy-le-grand); 2020 Sep; 66(6):81-85. PubMed ID: 33040790
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia.
Lu Y; Li Y; Chai X; Kang Q; Zhao P; Xiong J; Wang J
Gene; 2017 Apr; 607():41-46. PubMed ID: 28069548
[TBL] [Abstract][Full Text] [Related]
11. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
12. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
13. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
[TBL] [Abstract][Full Text] [Related]
15. TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway.
Wu Y; Hu Y; Yu X; Zhang Y; Huang X; Chen S; Li Y; Zeng C
Biochem Biophys Res Commun; 2019 Nov; 519(2):234-239. PubMed ID: 31493871
[TBL] [Abstract][Full Text] [Related]
16. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
[TBL] [Abstract][Full Text] [Related]
17. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
Wen F; Cao YX; Luo ZY; Liao P; Lu ZW
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670
[TBL] [Abstract][Full Text] [Related]
18. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
[TBL] [Abstract][Full Text] [Related]
19. The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells.
Zeng C; Liu S; Lu S; Yu X; Lai J; Wu Y; Chen S; Wang L; Yu Z; Luo G; Li Y
Mol Cancer; 2018 Aug; 17(1):130. PubMed ID: 30153828
[TBL] [Abstract][Full Text] [Related]
20. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
Wang XY; Sun GB; Wang YJ; Yan F
Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]